One in 20 Patients Misdiagnosed in America

A new study suggests that 12 million Americans receiving outpatient care are misdiagnosed every year, with a significant number of the misdiagnoses harming the patients.

The findings are being reported in the journal BMJ Quality and Safety.

Researchers estimate 5 percent misdiagnosis rate

Since actual figures of misdiagnoses don't exist, Texas researchers took data from three separate studies to create a pool of 3,000 medical records. From those records, they were able to ascertain a misdiagnosis rate of about 5 percent which, when extrapolated across all adults in the United States, totals about 12 million misdiagnoses annually.

"Not all misdiagnoses lead to any severe harm, but many do," Dr. Hardeep Singh, the study's lead author and a patient safety researcher at Baylor College of Medicine the Michael E. DeBakey VA Medical Center, both in Houston, told Reuters. "We can extrapolate that almost half of these could cause some amount of severe patient harm.

"Measuring the problem is the first step to actually trying to fix it."

Source: Reuters

Photo by Chance Agrella

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap